Azenta (NASDAQ:AZTA – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Volatility & Risk
Azenta has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Profitability
This table compares Azenta and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -10.01% | 1.40% | 1.17% |
| Nyxoah | -1,457.97% | -101.99% | -66.74% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.69 | -$55.76 million | ($1.30) | -26.73 |
| Nyxoah | $4.89 million | 31.13 | -$64.10 million | ($2.49) | -1.80 |
Azenta has higher revenue and earnings than Nyxoah. Azenta is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
99.1% of Azenta shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations and price targets for Azenta and Nyxoah, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 2 | 3 | 3 | 0 | 2.13 |
| Nyxoah | 1 | 0 | 3 | 0 | 2.50 |
Azenta currently has a consensus target price of $39.00, suggesting a potential upside of 12.23%. Nyxoah has a consensus target price of $12.67, suggesting a potential upside of 183.37%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts plainly believe Nyxoah is more favorable than Azenta.
Summary
Azenta beats Nyxoah on 7 of the 13 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
